Tuesday, September 25, 2018 2:45:26 PM
“We have a number of catalysts coming out over the next year”
“Firstly, we are in our Phase 1 Safety Study for our Psoriasis Cream and we’ll finish that study by the end of this quarter.”
“We intend to initiate Phase 1 studies in our Oral Disintegrating Tablet”
“We have a very high tech advanced nasal delivery system based on nanoparticle carriers and we’re hoping to go into our first animal studies.
“We’ll be looking to try and penetrate blood-brain barrier and that will also take place in the beginning first half of this year.”
“Moving into the second half of the year, we have a number of Phase 2 efficacy trials.”
Hmmm have a number of phase 2 trials second half of this year,maybe no need for phase 1 on other stuff that involves the cream as i stated in a previous post.
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM